MTOR and renal cell carcinoma: Given the association of RCC-FMS with alterations in the TSC/MTOR pathway, mTOR inhibitors (e.g., everolimus, temsirolimus) represent a potential targeted therapeutic option for advanced, metastatic, or inoperable cases, though clinical data remain limited (2).